RxDoctor Payments Data

Vinai Kumar Katragadda

Nephrology · Clarksville, TNNPI 1679835441

Payments from drug & device makers

$1,897in general payments, 2019–2025

Across 87 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$929
  • Boehringer Ingelheim$373
  • Otsuka America Pharmaceutical, Inc.$194
  • Travere Therapeutics, Inc.$105
  • Novartis$66
  • ANI Pharmaceuticals, Inc.$59
  • plus $172 from 8 others

What the payments were for

  • Food & beverage$1,62185%
  • Education$27615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,897 in reported general payments places this provider in the 55th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$320,305
Medicare patients
769
Services billed
3,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol283$275,135
JardianceEmpagliflozin124$140,829
LokelmaSodium Zirconium Cyclosilicate60$38,858
VeltassaPatiromer Calcium Sorbitex26$37,143
AuryxiaFerric Citrate17$28,419
KerendiaFinerenone15$18,410
InvokanaCanagliflozin15$8,872
Sevelamer Carbonate30$5,380
Calcium Acetate50$4,186
Losartan Potassium191$2,040
Nifedipine ErNifedipine51$1,807
Midodrine Hcl41$1,107
Lisinopril182$743
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$692
Hydralazine Hcl47$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$929$313,994343 claims
Boehringer IngelheimJardiance$373$140,829124 claims
Akebia Therapeutics IncAuryxia$25$28,41917 claims
BayerKerendia$35$18,41015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →